Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial

医学 单中心 紫杉醇 肿瘤科 内科学 腺癌 紫杉醇 吉西他滨 胰腺癌 化疗 癌症
作者
Yan Shi,Sui Zhang,Quanli Han,Jie Li,Huan Yan,Yao Lv,Huaiyin Shi,Rong Liu,Guanghai Dai
出处
期刊:Oncotarget [Impact Journals LLC]
卷期号:8 (54): 92401-92410 被引量:24
标识
DOI:10.18632/oncotarget.21359
摘要

// Yan Shi 1 , Sui Zhang 2 , Quanli Han 1 , Jie Li 3 , Huan Yan 1 , Yao Lv 1 , Huaiyin Shi 3 , Rong Liu 4 and Guanghai Dai 1 1 Medical Oncology Department 2, Chinese PLA General Hospital and Chinese PLA Medical School, Beijing, P.R. China 2 Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA 3 Pathology Department, Chinese PLA General Hospital and Chinese PLA Medical School, Beijing, P.R. China 4 Department of Hepatobiliary and Pancreatic Surgical Oncology, Chinese PLA General Hospital and Chinese PLA Medical School, Beijing, P.R. China Correspondence to: Guanghai Dai, email: daigh301@vip.sina.com Keywords: nab-paclitaxel, S-1, objective response rate, survival, advanced pancreatic adenocarcinoma Received: April 28, 2017 Accepted: August 28, 2017 Published: September 28, 2017 ABSTRACT This single-arm, phase II trial is to investigate efficacy and safety of nab-paclitaxel plus S-1 as first-line treatment in advanced pancreatic cancer. Nab-paclitaxel was administered at 120 mg/m 2 intravenously on day 1 and 8, S-1 was given twice a day orally on day 1-14 of each 21-day cycle, for 6 cycles. The primary endpoint was objective response rate (ORR), the secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. The ORR in intent-to-treat population (N=60) by either blinded independent review (BIR) or investigator assessment was 50.0%. Median PFS (mPFS) by BIR and median OS (mOS) were 5.6 months (95%CI, 4.6 to 6.6 m) and 9.4 months (95%CI, 8.0 to 10.8m), respectively. The most common grade 3 or 4 toxicities were leukopenia/neutropenia (35%) and fatigue (8.3%). Subgroup analyses based on BIR showed a remarkable ORR (>70%) was achieved in patients with female gender, ≥ 50% decline from baseline CA19-9, and developed grade 3 or 4 leukopenia/neutropenia. Remarkable survival benefit was statistically significant in female (mPFS: 7.7m, mOS: 18.2m), ≥ 50% decline from baseline CA19-9 (mPFS: 6.8m, mOS: 11.8m), objective responders (mPFS: 6.9m, mOS: 12.2m), and ECOG of 0 at baseline (mPFS: 7.5m, mOS: 16.1m). Nab-paclitaxel plus S-1 showed encouraging ORR and manageable toxicities, which is an effective alternative treatment regimen for advanced pancreatic cancer. ( https://clinicaltrials.gov/ number, NCT02124317)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lllllllll发布了新的文献求助10
刚刚
刚刚
Tsuki发布了新的文献求助10
刚刚
llllhh发布了新的文献求助10
刚刚
刚刚
1秒前
小道发布了新的文献求助10
1秒前
里予完成签到 ,获得积分10
1秒前
null的应助被xxcub采纳,获得10
1秒前
2秒前
李健的应助被优美的冷雪采纳,获得10
2秒前
肥鸟先飞完成签到 ,获得积分10
2秒前
2秒前
明亮的迎松完成签到,获得积分10
3秒前
3秒前
王彩娥完成签到 ,获得积分10
3秒前
3秒前
3秒前
4秒前
4秒前
丘比特的应助被完美的紊采纳,获得10
4秒前
4秒前
茉莉雨的应助被无聊的怀绿采纳,获得10
4秒前
wc发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
TRACEY发布了新的文献求助10
6秒前
6秒前
7秒前
赘婿的应助被nmlk采纳,获得10
7秒前
霓霓完成签到,获得积分10
7秒前
朴素旭尧完成签到,获得积分10
7秒前
qian完成签到,获得积分10
8秒前
徐翩跹完成签到,获得积分10
8秒前
梁寻完成签到,获得积分10
8秒前
顾矜的应助被zyx采纳,获得10
8秒前
gyh完成签到,获得积分10
8秒前
优秀颦发布了新的文献求助10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171477
求助须知:如何正确求助?哪些是违规求助? 9564248
关于积分的说明 21774106
捐赠科研通 7763073
什么是DOI,文献DOI怎么找? 3430972
关于科研通互助平台的介绍 2554805
邀请新用户注册赠送积分活动 2475887